This medical breakthrough is a significant step forward in treating Sickle Cell Disease SCD in Wisconsin, with the FDA’s recent approval of the gene-editing Casgevy therapy developed by CRISPR Therapeutics.
The therapy works by modifying a patient’s own stem cells, stopping the production of sickle cells, which are known to cause severe pain crises and life-threatening complications.
Children’s Wisconsin, through the MACC Fund Center for Cancer and Blood Disorders, is now offering this treatment to children aged 12 and older who suffer from severe SCD or transfusion-dependent thalassemia.
Community members, including patients and advocates like Tokara Henry and Starda Kelly-Howard, have expressed optimism and hope, emphasizing how this option offers a new chance for a healthier life.
With over 1,200 families affected by SCD in Wisconsin, this development could dramatically impact the quality of life for many.
Blood donations are crucial to support those undergoing treatment, as the national blood supply has hit low levels.
The upcoming Walk to Break the Sickle Cycle on October 12th in Lakeshore State Park is another way to raise awareness and support for SCD patients in Wisconsin.